|Videos|December 22, 2022
Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Signatera Is Submitted to Japan's PMDA for Companion Diagnostic Approval in MIBC
4
Colorectal Cancer Isn't the Only Gastrointestinal Cancer Rising in Young Adults
5